Rich Pharmaceuticals Competitors and Similar CompaniesClear all

Rich Pharmaceuticals's competitors and similar companies include United Biopharma, Symphogen, Immunomedics and SillaJen.

	Rich Pharmaceuticals Rich Pharmaceuticals is a biopharmaceutical company that is focused on the development of its lead product, RP-323, for the treatment of acute myelogenous leukemia in refractory patients.	United Biopharma United BioPharma is a company dedicated to the development and commercialization of monoclonal antibodies.	Symphogen Symphogen is a biotech company focused on oncology and immuno-oncology.	Immunomedics Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.	SillaJen SillaJen is a biotechnology company focused on engineering and developing oncolytic virus immunotherapeutics.
Founding Date	Founding Date N/A	Founding Date 2013	Founding Date 2000	Founding Date 1982	Founding Date 2003
Type	Type Public	Type Private	Type Private	Type Subsidiary	Type Public
Tags	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma	Tags Healthcare biotech oncology pharma
Locations	Locations Beverly Hills, US HQ	Locations TW HQ Yangzhou Shi, CN Hauppauge, US	Locations Ballerup, DK HQ Somerville, US	Locations Morris Plains, US HQ	Locations KR HQ San Francisco, US
Employees	Employees 1	Employees 393% decrease	Employees 196	Employees 8914% decrease	Employees 4316% increase
Financial
Revenue (est.)	Revenue (est.) $115k (FY, 2018)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $295k (FY, 2019)	Revenue (est.) ₩9.2b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods (₩1k) (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit $295k (FY, 2019)	Gross profit ₩9.9b (FY, 2025)
Net income	Net income ($1.7m) (FY, 2018)	Net income N/A	Net income N/A	Net income ($357.3m) (FY, 2019)	Net income (₩24.2b) (FY, 2025)
Funding
Total funding raised	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 387.2m	Total funding raised $ 30m	Total funding raised $ 12m